Die nichtalkoholische Steatohepatitis (NASH) als Ursache erhöhter Leberwerte

Die nichtalkoholische Steatohepatitis (NASH) ist die progrediente Verlaufsform der nichtalkoholischen Fettlebererkrankung (NAFLD) und durch eine erhöhte entzündliche Aktivität gekennzeichnet, die in einer Leberfibrose bzw. Leberzirrhose resultieren kann. NASH-Aktivität und Leberfibrose sind die prognoserelevanten Risikofaktoren, sodass eine rationale Stufendiagnostik, Identifikation von Risikopersonen und ein zielgerichteter Einsatz der therapeutischen Möglichkeiten entscheidend ist.

Abstract

Non-alcoholic steatohepatitis (NASH) is the progressive entity of non-alcoholic fatty liver disease (NAFLD) and characterised by increased inflammatory activity, potentially resulting in liver fibrosis and ultimately cirrhosis. NASH activity and hepatic fibrosis are the prognosis determinating risk factors – rational stepwise diagnostic approaches are urgently needed as therapeutic options beyond lifestyle modifications are limited.

Kernaussagen

• Die nichtalkoholische Fettlebererkrankung (NAFLD) ist die häufigste chronische Lebererkrankung und damit eine führende Ursache erhöhter Leberwerte.

• Ein Screening der Allgemeinbevölkerung auf eine NAFLD ist trotz der hohen Prävalenz nicht praktikabel und sollte daher mithilfe einfacher, nicht invasiver diagnostischer Verfahren auf Risikopopulationen (z.B. Adipositas, Typ-2-Diabetes) fokussiert werden.

• In der nicht zirrhotischen NAFLD sind insbesondere kardiovaskuläre Erkrankungen, metabolische Risikofaktoren und extrahepatische Tumorerkrankungen prognoserelevant.

• Leberfibrose (≥F3) und Leberzirrhose bestimmen die Prognose und sind die wichtigsten Risikofaktoren für hepatische Komplikationen, Morbidität und Mortalität.

• Es gibt keine spezifisch zugelassene, medikamentöse Therapie der NAFLD; Behandlungsstrategien beinhalten eine Lebensstilmodifikation, die Behandlung von Komorbiditäten und Komplikationen sowie ein regelmäßiges und interdisziplinäres Monitoring.

Schlüsselwörter

nichtalkoholische Fettlebererkrankung (NAFLD) - nichtalkoholische Steatohepatitis (NASH) - Leberfibrose - Risikostratifikation - nicht invasive Diagnostik

Keywords

Non-alcoholic fatty liver disease (NAFLD) - non-alcoholic steatohepatitis (NASH) - liver fibrosis - risk stratification - non-invasive diagnostics

Publication History

Article published online:
26 June 2023

• Literatur

• 1 Younossi Z, Tacke F, Arrese M. et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019; 69: 2672-2682
• 2 Younossi ZM, Golabi P, de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019; 71: 793-801
• 3 Simon TG, Roelstraete B, Khalili H. et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021; 70: 1375-1382
• 4 Tacke F, Canbay A, Bantel H. et al. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025. Z Gastroenterol 2022; 60: e733-e801
• 5 Dulai PS, Singh S, Patel J. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65: 1557-1565
• 6 Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V. et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 2018; 155: 443-457 e417
• 7 Bertot LC, Jeffrey GP, Wallace M. et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun 2017; 1: 53-60
• 8 Kanwal F, Shubrook JH, Adams LA. et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021; 161: 1657-1669
• 9 Ooi GJ, Mgaieth S, Eslick GD. et al. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. Obes Rev 2018; 19: 281-294
• 10 European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline P, Chair. et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689
• 11 Hernaez R, Lazo M, Bonekamp S. et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090
• 12 Bril F, Ortiz-Lopez C, Lomonaco R. et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 2015; 35: 2139-2146
• 13 Eddowes PJ, Sasso M, Allison M. et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156: 1717-1730
• 14 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020; 12: 125-138
• 15 Park CC, Nguyen P, Hernandez C. et al. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology 2017; 152: 598-607 e592
• 16 Loomba R, Wolfson T, Ang B. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60: 1920-1928
• 17 Vuppalanchi R, Noureddin M, Alkhouri N. et al. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021; 18: 373-392
• 18 Newsome PN, Buchholtz K, Cusi K. et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384: 1113-1124
• 19 Boland ML, Laker RC, Mather K. et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab 2020; 2: 413-431
• 20 Aminian A, Al-Kurd A, Wilson R. et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021; 326: 2031-2042
• 21 Hjorth S, Naslund I, Andersson-Assarsson JC. et al. Reoperations After Bariatric Surgery in 26 Years of Follow-up of the Swedish Obese Subjects Study. JAMA Surg 2019; 154: 319-326
• 22 Long MT, Zhang X, Xu H. et al. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology 2021; 73: 548-559
• 23 Perumpail RB, Wong RJ, Ahmed A. et al. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci 2015; 60: 3142-3148